Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611001002976
Ethics application status
Not yet submitted
Date submitted
19/09/2011
Date registered
20/09/2011
Date last updated
20/09/2011
Type of registration
Prospectively registered
Titles & IDs
Public title
In pre-diabetic adults aged 30-65 does zinc supplementation improve glycemic control over 6 months compared with placebo?
Query!
Scientific title
In pre-diabetic adults aged 30-65 does zinc supplementation over 6 months compared with placebo improve glycemic control?
Query!
Secondary ID [1]
263063
0
Nil
Query!
Universal Trial Number (UTN)
Nil
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Prediabetes
270797
0
Query!
Condition category
Condition code
Metabolic and Endocrine
270990
270990
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
30 milligram zinc sulphate tablet daily over a period of six months
Query!
Intervention code [1]
269414
0
Prevention
Query!
Intervention code [2]
269419
0
Treatment: Drugs
Query!
Comparator / control treatment
30 milligram placebo tablet daily over a period of six months
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
279654
0
Decrease of fasting serum glucose level by 5%
Query!
Assessment method [1]
279654
0
Query!
Timepoint [1]
279654
0
After six months of daily treatment by 30mg zinc sulphate tablet
Query!
Secondary outcome [1]
294134
0
Increase of insulin sensitivity by 5%. We will determine the insulin sensitivity at the baseline and after the intervention using HOMA-2 calculator by measuring fasting blood glucose level and serum insulin level.
Query!
Assessment method [1]
294134
0
Query!
Timepoint [1]
294134
0
After six months of daily treatment by 30mg zinc sulphate tablet
Query!
Secondary outcome [2]
294135
0
Increase of pancreatic beta cell function by 5%. We will determine the pancreatic beta cell function at the baseline and after the intervention using HOMA-2 calculator by measuring fasting blood glucose level and serum insulin level.
Query!
Assessment method [2]
294135
0
Query!
Timepoint [2]
294135
0
After six months of daily treatment by 30mg zinc sulphate tablet
Query!
Secondary outcome [3]
294144
0
Decrease of insulin resistance by 5%. We will determine the insulin resistance at the baseline and after the intervention using HOMA-2 calculator by measuring fasting blood glucose level and serum insulin level.
Query!
Assessment method [3]
294144
0
Query!
Timepoint [3]
294144
0
After six months of daily treatment by 30mg zinc sulphate tablet
Query!
Eligibility
Key inclusion criteria
1. 30 to 65 yrs with BMI=23-27kg/m2 (overweight for South Asian Population) and;
2. Oral glucose tolerance test (GTT) with results 8mmol/l to 11mmol/l at the beginning.
3. Diagnosed as ‘prediabetic’ following a previous GTT within last 12 months.
4. Resident of Dhaka city corporation and likely to live in the city during the study period.
Query!
Minimum age
30
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
These include: known diabetes mellitus, pregnancy, renal insufficiency, cardiovascular disease, thyroid disease, liver disease or any other chronic disease, multiple co-morbidities, physical inactivity (wheelchair bound), psychiatric disorders, gastrointestinal disorders, pharmacology agents that may interfere with the intervention (for example, diuretics, and complementary medicines), morbid obesity. These will be determined from the results of the survey, clinical assessment and pathology testing.
These criteria are based on previous studies and are used to minimise confounding and drug interactions that may interfere with the intervention.
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Having fulfilled all inclusion criteria, written consent will be obtained from each participant before recruiting into the study. Each participant will then attend the BIHS clinic to be randomized. Prior to attending the clinic, participants will be mailed a food frequency questionnaire to obtain information on usual dietary intake
Given the small sample size, block randomisation will be done to ensure equal number of participants in treatment and placebo arms of the trials. Allocation will be concealed by phoning to the central co-ordinating office. Participants will be randomly allocated to active (30mg/day zinc gluconate) or control tablets/capsules, the latter being a tablet/capsule identical in appearance to the intervention. Following randomisation participants will receive the intervention or placebo along with a BIHS pathology form to have the following measured: FBC, GTT, Serum Zinc, Serum insulin, HbA1C, Lipid Profile, Blood urea and serum creatinine, and CRP. All participants will also receive the Australian Diabetic Association guide to health eating and lifestyle.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated BLOCK randomization schedule
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/10/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
40
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
3849
0
Bangladesh
Query!
State/province [1]
3849
0
Dhaka
Query!
Funding & Sponsors
Funding source category [1]
269884
0
University
Query!
Name [1]
269884
0
The University of Newcastle
Query!
Address [1]
269884
0
Centre for Clinical Epidemiology and Biostatistics (CCEB)
School of Medicine and Public Health, Faculty of Health
The University of Newcastle
David Maddision Bulding
Level 2, Corner of King and Watt Street
Newcastle, NSW 2300
Australia
Query!
Country [1]
269884
0
Australia
Query!
Primary sponsor type
University
Query!
Name
The University of Newcastle
Query!
Address
Centre for Clinical Epidemiology and Biostatistics (CCEB)
School of Medicine and Public Health, Faculty of Health
The University of Newcastle
David Maddision Bulding
Level 2, Corner of King and Watt Street
Newcastle, NSW 2300
Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
268900
0
None
Query!
Name [1]
268900
0
Query!
Address [1]
268900
0
Query!
Country [1]
268900
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
271852
0
Human Research Ethics Committee (HREC), The University of Newcastle
Query!
Ethics committee address [1]
271852
0
HREC The University of Newcastle University Drive, Callaghan Campus Newcastle, NSW 2308, Australia. Fax: 4921 7164 Email: human-ethics@newcastle.edu.au
Query!
Ethics committee country [1]
271852
0
Australia
Query!
Date submitted for ethics approval [1]
271852
0
20/07/2011
Query!
Approval date [1]
271852
0
15/08/2011
Query!
Ethics approval number [1]
271852
0
H-2011-0194
Query!
Summary
Brief summary
Zinc has been shown to improve blood glucose levels and insulin resistance in diabetic subjects in a small number of animal and human observation and interventional studies. (2-9)To extend the results of these studies, we propose to perform a pilot, double blinded randomised controlled trial in an at risk pre-diabetic adult population in Bangladesh aged 30-65 years to determine if zinc supplementation can reduce blood glucose and insulin resistance compared to placebo over a six months period. Aims To perform a pilot double blinded randomized controlled trial in an at-risk pre-diabetic population aged 30-65 years to determine if zinc supplementation will: 1. reduce impaired glucose tolerance levels 2. reduce insulin resistance 3. increase insulin sensitivity 4. increase pancreatic beta cell function Hypotheses 1. In a pilot double blinded randomised controlled trial of an at-risk pre-diabetic population of those 30-65 years, zinc supplementation (30mg/day) will decrease fasting serum glucose by 5% over six months compared to a placebo treatment. 2. In a pilot double blinded randomised controlled trial of an at-risk pre-diabetic population of those 30-65 years, zinc supplementation (30mg/day) will decrease insulin resistance by 5% over six months compared to a placebo treatment. 3. In a pilot double blinded randomised controlled trial of an at-risk pre-diabetic population of those 30-65 years, zinc supplementation (30mg/day) will increase insulin sensitivity by 5% over six months compared to a placebo treatment. 4. In a pilot double blinded randomised controlled trial of an at-risk pre-diabetic population of those 30-65 years, zinc supplementation (30mg/day) will increase pancreatic beta cell function by 5% over six months compared to a placebo treatment.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
33177
0
Query!
Address
33177
0
Query!
Country
33177
0
Query!
Phone
33177
0
Query!
Fax
33177
0
Query!
Email
33177
0
Query!
Contact person for public queries
Name
16424
0
Dr Mohammad Abul Hasnat
Query!
Address
16424
0
Senior Lecturer
CCEB, School of Medicine and Public Health
Faculty of Health
Level 2, David Maddision Building
Corner of King and Watt Street
The University of Newcastle
Newcastle, NSW 2300
Australia
Query!
Country
16424
0
Australia
Query!
Phone
16424
0
+61 2 49138200, +61 (0) 412141971
Query!
Fax
16424
0
+61 2 49138148
Query!
Email
16424
0
[email protected]
Query!
Contact person for scientific queries
Name
7352
0
Dr Mohammad Abul Hasnat
Query!
Address
7352
0
Senior Lecturer
CCEB, School of Medicine and Public Health
Faculty of Health
Level 2, David Maddision Building
Corner of King and Watt Street
The University of Newcastle
Newcastle, NSW 2300
Australia
Query!
Country
7352
0
Australia
Query!
Phone
7352
0
+61 2 49138200, +61 (0) 412141971
Query!
Fax
7352
0
+61 2 49138148
Query!
Email
7352
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF